CY1122202T1 - Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης - Google Patents
Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινηςInfo
- Publication number
- CY1122202T1 CY1122202T1 CY20191101107T CY191101107T CY1122202T1 CY 1122202 T1 CY1122202 T1 CY 1122202T1 CY 20191101107 T CY20191101107 T CY 20191101107T CY 191101107 T CY191101107 T CY 191101107T CY 1122202 T1 CY1122202 T1 CY 1122202T1
- Authority
- CY
- Cyprus
- Prior art keywords
- determination
- infectious disease
- risk
- primary non
- patients suffering
- Prior art date
Links
- 108010048233 Procalcitonin Proteins 0.000 title abstract 3
- 230000003115 biocidal effect Effects 0.000 title abstract 3
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 title abstract 3
- 208000031662 Noncommunicable disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09157886 | 2009-04-14 | ||
| PCT/EP2010/002279 WO2010118855A1 (en) | 2009-04-14 | 2010-04-14 | Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin |
| EP10717531.7A EP2419741B1 (en) | 2009-04-14 | 2010-04-14 | Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122202T1 true CY1122202T1 (el) | 2020-11-25 |
Family
ID=40886944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101107T CY1122202T1 (el) | 2009-04-14 | 2019-10-24 | Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9046532B2 (https=) |
| EP (1) | EP2419741B1 (https=) |
| JP (1) | JP5650718B2 (https=) |
| CN (2) | CN105334330A (https=) |
| CY (1) | CY1122202T1 (https=) |
| DK (1) | DK2419741T3 (https=) |
| ES (1) | ES2751105T3 (https=) |
| HK (1) | HK1221766A1 (https=) |
| HR (1) | HRP20191862T1 (https=) |
| HU (1) | HUE046182T2 (https=) |
| LT (1) | LT2419741T (https=) |
| PL (1) | PL2419741T3 (https=) |
| PT (1) | PT2419741T (https=) |
| SI (1) | SI2419741T1 (https=) |
| WO (1) | WO2010118855A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2836841B1 (en) * | 2012-04-12 | 2022-01-05 | B.R.A.H.M.S GmbH | Prognosis of adverse events in patients with suspected chronic heart failure |
| CN105528511A (zh) * | 2014-10-25 | 2016-04-27 | 潘一琦 | 一种远程诊疗对比式问诊方法及其系统 |
| CN107301319B (zh) * | 2017-06-26 | 2021-02-26 | 济南市儿童医院 | 儿科临床及科研中抗菌药物使用危险评估系统 |
| JP7444776B2 (ja) * | 2017-12-20 | 2024-03-06 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス |
| EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314804A (en) * | 1992-03-24 | 1994-05-24 | Serim Research Corporation | Test for Helicobacter pylori |
| DE19600875C1 (de) * | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
| ATE395364T1 (de) * | 1999-12-22 | 2008-05-15 | Dade Behring Marburg Gmbh | Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung |
| JP2005522669A (ja) * | 2001-08-20 | 2005-07-28 | バイオサイト インコーポレイテッド | 卒中および脳損傷の診断マーカーおよびその使用方法 |
| US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| DE102005034174A1 (de) * | 2005-07-21 | 2007-02-08 | B.R.A.H.M.S Ag | Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen |
| FR2894675B1 (fr) * | 2005-12-14 | 2008-06-27 | Assist Publ Hopitaux De Paris | Distinction des meningites bacteriennes et virales |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| CN103123359B (zh) * | 2007-08-03 | 2015-07-29 | B.R.A.H.M.S有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
-
2010
- 2010-04-14 JP JP2012505086A patent/JP5650718B2/ja active Active
- 2010-04-14 DK DK10717531T patent/DK2419741T3/da active
- 2010-04-14 PL PL10717531T patent/PL2419741T3/pl unknown
- 2010-04-14 HU HUE10717531A patent/HUE046182T2/hu unknown
- 2010-04-14 CN CN201510626744.9A patent/CN105334330A/zh active Pending
- 2010-04-14 CN CN201080016849.8A patent/CN102395888B/zh active Active
- 2010-04-14 SI SI201031945T patent/SI2419741T1/sl unknown
- 2010-04-14 WO PCT/EP2010/002279 patent/WO2010118855A1/en not_active Ceased
- 2010-04-14 ES ES10717531T patent/ES2751105T3/es active Active
- 2010-04-14 US US13/264,252 patent/US9046532B2/en active Active
- 2010-04-14 HR HRP20191862TT patent/HRP20191862T1/hr unknown
- 2010-04-14 EP EP10717531.7A patent/EP2419741B1/en not_active Revoked
- 2010-04-14 LT LT10717531T patent/LT2419741T/lt unknown
- 2010-04-14 PT PT107175317T patent/PT2419741T/pt unknown
-
2015
- 2015-03-30 US US14/672,801 patent/US9810699B2/en active Active
-
2016
- 2016-08-16 HK HK16109795.0A patent/HK1221766A1/zh unknown
-
2017
- 2017-11-06 US US15/804,282 patent/US20180052179A1/en not_active Abandoned
-
2019
- 2019-10-24 CY CY20191101107T patent/CY1122202T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1221766A1 (zh) | 2017-06-09 |
| WO2010118855A1 (en) | 2010-10-21 |
| HRP20191862T1 (hr) | 2019-12-27 |
| EP2419741A1 (en) | 2012-02-22 |
| HUE046182T2 (hu) | 2020-02-28 |
| CN102395888B (zh) | 2017-05-03 |
| PL2419741T3 (pl) | 2020-01-31 |
| JP2012523573A (ja) | 2012-10-04 |
| LT2419741T (lt) | 2019-11-11 |
| EP2419741B1 (en) | 2019-07-31 |
| US9810699B2 (en) | 2017-11-07 |
| DK2419741T3 (da) | 2019-11-04 |
| JP5650718B2 (ja) | 2015-01-07 |
| US20180052179A1 (en) | 2018-02-22 |
| US20120100635A1 (en) | 2012-04-26 |
| US20150247871A1 (en) | 2015-09-03 |
| ES2751105T3 (es) | 2020-03-30 |
| US9046532B2 (en) | 2015-06-02 |
| SI2419741T1 (sl) | 2019-12-31 |
| PT2419741T (pt) | 2019-11-04 |
| CN105334330A (zh) | 2016-02-17 |
| CN102395888A (zh) | 2012-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122202T1 (el) | Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης | |
| CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
| CY1121872T1 (el) | Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων | |
| WO2018089693A3 (en) | Methods for determining and monitoring gastrointestinal inflammation | |
| MX385872B (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer | |
| CY1116089T1 (el) | Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων | |
| BR112013013460A8 (pt) | métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total | |
| CY1115798T1 (el) | Μεθοδος για τη διαγνωση καρκινων που εκφραζουν μια κολοβωμενη παραλλαγη του υποδοχεα her2 | |
| AR098155A1 (es) | Métodos para diagnosticar y tratar trastornos eosinofílicos | |
| CY1115871T1 (el) | Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας | |
| MX362514B (es) | Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. | |
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| CY1119451T1 (el) | Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο | |
| MX2020012548A (es) | Métodos para el tratamiento de mieloma múltiple y uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoiso indolin-4-il)oxi)metil)bencil)piperazin-1- il)-3-fluorobenzonitril o. | |
| MX355416B (es) | Biomarcadores de cancer de pulmon y usos de los mismos. | |
| BR112016002845A2 (pt) | composições e métodos para tratar condições associadas ao complemento | |
| MX2021003164A (es) | Perfiles de hidroximetilación de adn circulante en la evaluación de lesiones pancreáticas. | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| HK1213892A1 (zh) | Tec家族激酶抑制剂疗法的伴随诊断 | |
| CY1119867T1 (el) | Αναστολεις vap-1 για χρηση στη θεραπεια ινωτικων καταστασεων | |
| MX386919B (es) | Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática. | |
| AR080361A1 (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) | |
| MX2015000686A (es) | Metodo para detectar cancer. | |
| MX2013011431A (es) | Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico. | |
| MX2022001087A (es) | Ergotioneina, s-metil-ergotioneina, y usos de las mismas. |